[1] Singletary SE. Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Am. J. Surg., vol. 182, Am J Surg; 2001, p. 341–6. https://doi.org/10.1016/S0002-9610(01)00724-3.
[2] Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: Multidisciplinary considerations of benefits and risks. Cancer 2003;98:1150–60. https://doi.org/10.1002/cncr.11603.
[3] Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 2008;26:778–85. https://doi.org/10.1200/JCO.2007.15.0235.
[4] Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson cancer center experience. J Clin Oncol 2004;22:2303–12. https://doi.org/10.1200/JCO.2004.09.062.
[5] Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006;24:2019–27. https://doi.org/10.1200/JCO.2005.04.1665.
[6] Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 1997;15:2483–93. https://doi.org/10.1200/JCO.1997.15.7.2483.
[7] Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001:96–102. https://doi.org/10.1093/oxfordjournals.jncimonographs.a003469.
[8] Van der Hage JA, Van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001;19:4224–37. https://doi.org/10.1200/JCO.2001.19.22.4224.
[9] Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer 2001;37:189–97. https://doi.org/10.1016/S0959-8049(00)00353-1.
[10] Thirlaway K, Fallowfield L, Cuzick J. The sexual activity questionnaire: A measure of women’s sexual functioning. Qual Life Res 1996;5:81–90. https://doi.org/10.1007/BF00435972.
[11] Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018;19:27–39. https://doi.org/10.1016/S1470-2045(17)30777-5.
[12] Golshan M, Loibl S, Wong SM, Houber JB, O’Shaughnessy J, Rugo HS, et al. Breast Conservation after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results from the BrighTNess Randomized Clinical Trial. JAMA Surg 2020;155:195410. https://doi.org/10.1001/jamasurg.2019.5410.
[13] Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–85. https://doi.org/10.1200/JCO.1998.16.8.2672.
[14] JAVA. Declaration of Helsinki World Medical Association Declaration of Helsinki. Bull World Heal Organ 2013;79:373–4. https://doi.org/S0042-96862001000400016 [pii].
[15] Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. Int J Surg 2012. https://doi.org/10.1016/j.ijsu.2011.10.001.
[16] Masood S. Neoadjuvant chemotherapy in breast cancers. Women’s Heal 2016;12:480–91. https://doi.org/10.1177/1745505716677139.
[17] Cheng H, Clymer JW, Ferko NC, Patel L, Soleas IM, Cameron CG, et al. A systematic review and meta-analysis of harmonic technology compared with conventional techniques in mastectomy and breast-conserving surgery with lymphadenectomy for breast cancer. Breast Cancer Targets Ther 2016;8:125–40. https://doi.org/10.2147/BCTT.S110461.
[18] Almahariq MF, Quinn TJ, Siddiqui Z, Jawad MS, Chen PY, Gustafson GS, et al. Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer. Radiother Oncol 2020;142:186–94. https://doi.org/10.1016/j.radonc.2019.09.018.
[19] Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005;92:14–23. https://doi.org/10.1002/bjs.4840.
[20] Selli C, Sims AH. Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research. Breast Cancer Basic Clin Res 2019;13. https://doi.org/10.1177/1178223419829072.
[21] Debled M, Macgrogan G, Breton-Callu C, Ferron S, Hurtevent G, Fournier M, et al. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude. Eur J Cancer 2015;51:697–704. https://doi.org/10.1016/j.ejca.2015.01.063.
[22] Vergine M, Scipioni P, Garritano S, Colangelo M, Di Paolo A, Livadoti G, et al. Breast-conserving surgery after neoadjuvant chemotherapy in patients with locally advanced cancer. Preliminary results. G Di Chir 2013;34:254–6. https://doi.org/10.11138/gchir/2013.34.9.254.
[23] Cho JH, Park JM, Park HS, Park S, Kim S Il, Park BW. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. J Surg Oncol 2013;108:531–6. https://doi.org/10.1002/jso.23439.
[24] Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: Surgical results from CALGB 40603 (Alliance). Ann. Surg., vol. 262, Lippincott Williams and Wilkins; 2015, p. 434–8. https://doi.org/10.1097/SLA.0000000000001417.
[25] Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera G V., et al. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol 2009;16:1606–11. https://doi.org/10.1245/s10434-009-0402-z.
[26] Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, et al. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. Eur J Cancer 2018;97:1–6. https://doi.org/10.1016/j.ejca.2018.03.023.
[27] Masood S. Neoadjuvant chemotherapy in breast cancers. Women’s Heal 2016;12:480–91. https://doi.org/10.1177/1745505716677139.
[28] Bartelink H, Horiot J-C, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation. N Engl J Med 2001;345:1378–87. https://doi.org/10.1056/nejmoa010874.
[29] Zhou X, Li Y. Local Recurrence after Breast-Conserving Surgery and Mastectomy Following Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer-a Meta-Analysis. Breast Care 2016;11:345–51. https://doi.org/10.1159/000450626.
[30] Touboul E, Lefranc JP, Blondon J, Buffat L, Deniaud E, Belkacémi Y, et al. Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Radiother Oncol 1997;42:219–29. https://doi.org/10.1016/S0167-8140(97)01923-3.
[31] Ishitobi M, Ohsumi S, Inaji H, Ohno S, Shigematsu H, Akiyama F, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: Risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer 2012;118:4385–93. https://doi.org/10.1002/cncr.27377.
[32] Mukhtar RA, Yau C, Rosen M, Tandon VJ, Hylton N, Esserman LJ. Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 2013;20:3823–30. https://doi.org/10.1245/s10434-013-3038-y.